Hollywood, FL—The National Comprehensive Cancer Network (NCCN) now recommends nivolumab (Opdivo) as subsequent therapy for metastatic squamous non–small-cell lung cancer (NSCLC) after its recent FDA approval.
  • 4-Year Employer Trends and Value-Based Oncology Coverage–Related Findings from a National Employer Survey
  • Willingness to Pay for Treatment Among Women with Metastatic Breast Cancer
  • Current Practices in the Use of Next-Generation Sequencing: A Steep Learning Curve?
  • Using Data to Improve Quality of Care and Process Sheryl Riley
  • Treatment-Sequencing Patterns of Novel Agents in Patients with Prostate Cancer
  • Prostate Cancer Assay Improves Treatment Decisions for Patients with Early-Stage Disease
  • Defining Value in Oncology: Perspectives from Patients with Metastatic Breast Cancer
  • Examining Experiences of Patients Currently Being Treated with Abiraterone Acetate for Metastatic Castrate-Resistant...
  • Myeloid Growth Factor Utilization in a Commercial and Medicare Population: Phase 1 of a Quality Improvement Initiative
  • Improving the Awareness, Identification, and Management of Sarcopenic Obesity: An Evidence-Based Toolbox
  • Measuring the Value of Telephone Distress Screening and Referral on Resource Utilization and Distress in Patients with...
  • Demonstrating Return on Investment for Stakeholders in a Care Coordination Program
  • Budget Impact Analysis of Abiraterone Acetate plus Prednisone versus Enzalutamide for the Treatment of Patients with...
  • Budget Impact Analysis of Ibrutinib for Patients with Previously Treated Mantle-Cell Lymphoma
  • Cost-Effectiveness of Octreotide LAR versus Lanreotide Depot in the Treatment of Metastatic Gastrointestinal...
  • Patterns of Utilization of Bortezomib Retreatment in Patients with Relapsed and/or Refractory Multiple Myeloma Who...
  • Utilization Beyond Traditional Oncology Care Management: Utilizing Multiple Data Sets and Clinical Tools to Improve the...
  • Utilization of the New Agents Carfilzomib and Pomalidomide in Relapsed and/or Refractory Multiple Myeloma: Analysis...
  • Economic Impact of a Novel Circulating Tumor DNA Test for Third-Generation EGFR TKI Biomarker Testing in NSCLC
Chicago, IL—Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy with olaparib (Lynparza) for relapsed, platinum-sensitive ovarian cancer would meet conventional standards of cost-effectiveness only if the drug price decreased by ≥66%, according to a modeling study.
Chicago, IL—The addition of bevaciz­umab (Avastin) to standard chemotherapy extended survival in women with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone in the phase 3 randomized controlled GOG0213 trial. The results were presented at the 2015 Society of Gynecologic Oncology annual meeting.
  • Bortezomib Shows Efficacy as Frontline Therapy in Mantle-Cell Lymphoma
  • Goserelin Prevents Ovarian Failure in Breast Cancer
  • Regulation of E-Cigarettes and Other Electronic Nicotine Delivery Systems Needed
Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guideline allows for the upfront use of docetaxel (Taxotere) in some men with castration-resistant prostate cancer (CRPC). This and other systemic therapies represent the most significant changes in the updated guideline for the treatment of patients with metastatic CRPC, said Andrew J. Armstrong, MD, ScM, Co­-Leader, Genitourinary Oncology Research Program, Duke Cancer Institute, Durham, NC, at the 2015 NCCN annual conference.
Hollywood, FL—Value-based decision-making at the bedside can be fraught with obstacles, with no clear agreement on what constitutes value, and for whom. In addition, the myriad insurance plans preclude uniform treatment strategies, despite clinical pathways and guidelines intended to reduce variation in care. Finally, value is becoming more difficult to achieve in oncology as each benefit becomes more expensive, with the cost of new therapies outpacing inflation.
Hollywood, FL—A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment if needed, said Peter G. Shields, MD, Deputy Director, Comprehensive Cancer Center, James Cancer Hospital, Columbus, OH, at the 2015 National Comprehensive Cancer Network (NCCN) conference.
Hollywood, FL—Watch and wait remains the standard of care for patients with asymptomatic early-stage chronic lymphocytic leukemia (CLL), even for high-risk patients, but once therapy is indicated, targeted agents may supplant chemotherapy in the first-line treatment setting, said William G. Wierda, MD, PhD, Center Medical Director, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2015 National Comprehensive Cancer Network (NCCN) annual conference.
Orlando, FL—Patients with urologic cancer who are readmitted after a surgery to a second hospital and not to their original hospital are more likely to have complications than patients readmitted to their original surgical hospital, according to findings presented at the 2015 Genitourinary Cancers Symposium.
Page 1 of 3
Results 1 - 10 of 24
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology